Ars Pharmaceuticals, Inc. (SPRY) — SEC Filings
Ars Pharmaceuticals, Inc. (SPRY) — 29 SEC filings. Latest: 10-Q (Nov 10, 2025). Includes 14 8-K, 6 10-Q, 3 SC 13D/A.
View Ars Pharmaceuticals, Inc. on SEC EDGAR
Overview
Ars Pharmaceuticals, Inc. (SPRY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: ARS Pharmaceuticals, Inc. (SPRY) reported a significant increase in product revenue for the nine months ended September 30, 2025, reaching $51.863 million, up from $0.568 million in the same period of 2024. Total revenue also surged to $56.191 million from $2.568 million year-over-year. Despite this
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral. The dominant filing sentiment for Ars Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Ars Pharmaceuticals, Inc. (SPRY) has filed 6 10-Q, 14 8-K, 2 DEF 14A, 2 10-K, 1 10-Q/A, 3 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of SPRY's 27 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $56,191,000 |
| Net Income | -$129,974,000 |
| EPS | N/A |
| Debt-to-Equity | 1.52 |
| Cash Position | $59,557,000 |
| Operating Margin | N/A |
| Total Assets | $372,803,000 |
| Total Debt | $96,229,000 |
Key Executives
- Kathleen Scott
- Peter Kolchinsky
- Rajiv Shah
- Abigail P. Johnson
Industry Context
The epinephrine market is critical for treating severe allergic reactions. ARS Pharmaceuticals is aiming to disrupt the traditional injectable market with its intranasal delivery system, neffy. The company faces competition from established players offering injectable epinephrine, but its novel delivery method could offer advantages in terms of ease of use and patient preference.
Top Tags
10-Q (5) · pharmaceuticals (5) · financials (4) · disclosure (4) · material-definitive-agreement (3) · amendment (3) · ARS Pharmaceuticals (3) · Biotechnology (2) · Pharmaceuticals (2) · Commercialization (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenue | $51.863M | Increased from $0.568M in 2024 for the nine months ended September 30, 2025, indicating significant sales growth. |
| Net Loss | $129.974M | Widened from $41.936M in 2024 for the nine months ended September 30, 2025, highlighting increased operational costs. |
| Selling, General and Administrative Expenses | $170.167M | Increased from $36.183M in 2024 for the nine months ended September 30, 2025, reflecting aggressive commercialization. |
| Term Loans, Net | $96.229M | New debt incurred as of September 30, 2025, significantly increasing total liabilities. |
| Cash and Cash Equivalents | $59.557M | Increased from $50.817M at December 31, 2024, partly due to the new term loan. |
| Total Liabilities | $225.148M | More than doubled from $94.355M at December 31, 2024, primarily due to the new term loan. |
| Research and Development Expenses | $9.738M | Decreased from $16.553M in 2024 for the nine months ended September 30, 2025, suggesting a shift in focus. |
| Shares Outstanding | 98,848,611 | As of November 6, 2025, indicating the total number of common shares. |
| Acquisition Value | $1.0B | Total cash consideration for ARS Pharmaceuticals |
| Per Share Price | $21.50 | Cash to be paid to ARS shareholders |
| Net Loss (Q2 2025) | $44.88M | Increased from $12.52M in Q2 2024, indicating higher operational costs. |
| Total Revenue (Q2 2025) | $15.72M | Significantly up from $0.50M in Q2 2024, driven by neffy product sales. |
| SG&A Expenses (Q2 2025) | $54.31M | Jumped from $8.94M in Q2 2024, reflecting heavy commercialization investment. |
| Net Loss (YTD Q2 2025) | $78.82M | Widened from $22.81M in YTD Q2 2024, showing sustained losses. |
| Total Revenue (YTD Q2 2025) | $23.69M | Increased from $0.50M in YTD Q2 2024, primarily from product sales. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a similar ownership percentage in ARS Pharmaceuticals for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ars Pharmaceuticals, Inc. (SPRY)?
Ars Pharmaceuticals, Inc. has 29 recent SEC filings from Feb 2024 to Nov 2025, including 14 8-K, 6 10-Q, 3 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SPRY filings?
Across 29 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 26 neutral. The dominant sentiment is neutral.
Where can I find Ars Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ars Pharmaceuticals, Inc. (SPRY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ars Pharmaceuticals, Inc.?
Key financial highlights from Ars Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SPRY?
The investment thesis for SPRY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ars Pharmaceuticals, Inc.?
Key executives identified across Ars Pharmaceuticals, Inc.'s filings include Kathleen Scott, Peter Kolchinsky, Rajiv Shah, Abigail P. Johnson.
What are the main risk factors for Ars Pharmaceuticals, Inc. stock?
Of SPRY's 27 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Ars Pharmaceuticals, Inc.?
Recent forward-looking statements from Ars Pharmaceuticals, Inc. include guidance on {"claim":"FMR LLC will maintain a similar ownership percentage in ARS Pharmaceuticals for the foreseeable future.","enti.